Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy (Q35874064)

10 August 2017

1 reference

title

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy (English)

1 reference

Mycobacterium avium avium

10 August 2017

anti-retroviral agent

0 references

patient

0 references

1 reference

3

Richard E Chaisson

1 reference

10 August 2017

1

Petros C Karakousis

1 reference

10 August 2017

Richard D Moore

2

1 reference

10 August 2017

1 September 2004

1 reference

Lancet Infectious Diseases

10 August 2017

1 reference

10 August 2017

4

1 reference

10 August 2017

9

1 reference

10 August 2017

557-565

1 reference

Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Natural History of Disseminated Mycobacterium avium Complex Infection in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clinical and laboratory findings of disseminated Mycobacterium avium complex infection (DMAC) in a pair matched case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clinical features and outcome in disseminated mycobacterial diseases in AIDS patients in Taiwan.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Impact of opportunistic disease on survival in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency sy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Viral load as an independent risk factor for opportunistic infections in HIV-infected adults and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

In vivo activities of newer rifamycin analogs against Mycobacterium avium infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of patients with acute exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Phase III, randomized, double-blind study of clarithromycin extended-release and immediate-release formulations in the treatment of adult patients with acute maxillary sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical R

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Mycobacterium avium strains resistant to clarithromycin and azithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Effect of combined therapy with ansamycin, clofazimine, ethambutol, and isoniazid for Mycobacterium avium infection in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Quadruple-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Efficacy of rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. The Rifabutin Treatment Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Liposome-encapsulated gentamicin treatment of Mycobacterium avium-Mycobacterium intracellulare complex bacteremia in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Thrice-Weekly Clarithromycin-Containing Regimen for Treatment of Mycobacterium kansasii Lung Disease: Results of a Preliminary Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2804%2901130-2

7 January 2021

10.1016/S1473-3099(04)01130-2

Identifiers

DOI

1 reference

release_jfxuwsrct5ginph53icsw45w7i

10 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/jfxuwsrct5ginph53icsw45w7i

24 November 2022

mapped directly with Wikidata item

PubMed ID

15336223

1 reference

PubMed ID

15336223